ERBB2 and breast carcinoma: This study demonstrated efficacy in HER2-positive breast cancer patients previously treated with trastuzumab, taxanes, and TKI-containing treatments, achieving a CNS CBR of 34.4%, a CNS ORR of 25.0%, and a median CNS PFS of 5.6 months.